• head_banner_01

OEM China Diphenylacetonitrile Uses - Desmopressin Acetate to Treat central Diabetes Insipidus – Gentolex

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

We have a professional, efficiency team to provide quality service for our customer. We always follow the tenet of customer-oriented, details-focused for Glucagon, 660-27-5, 850140-72-6, Our company is dedicated to providing customers with high and stable quality products at competitive price, making every customer satisfied with our products and services.
OEM China Diphenylacetonitrile Uses - Desmopressin Acetate to Treat central Diabetes Insipidus – Gentolex Detail:

Product Detail

Name  Desmopressin
CAS number  16679-58-6
Molecular formula  C46H64N14O12S2
Molecular weight  1069.22
EINECS Number  240-726-7
Specific rotation  D25 +85.5 ± 2° (calculated for the free peptide)
Density  1.56±0.1 g/cm3(Predicted)
RTECS No.  YW9000000
Storage conditions  Store at 0°C
Solubility  H2O:soluble20mg/mL, clear, colorless
Acidity coefficient  (pKa) 9.90±0.15 (Predicted)

Synonyms

MPR-TYR-PHE-GLN-ASN-CYS-PRO-D-ARG-GLY-NH2; MINIRIN; [DEAMINO1, DARG8] VASOPRESSIN; [DEAMINO-CYS1, D-ARG8]-VASOPRESSIN; DDAVP, HUMAN; DESMOPRESSIN; DESMOPRESSIN, HUMAN; DESAMINO-[D-ARG8] VASOPRESSIN

Indications

(1) Treatment of central diabetes insipidus. After the drug can reduce urinary excretion, reduce urinary frequency and reduce nocturia.

(2) Treatment of nocturnal enuresis (patients aged 5 years or older).

(3) Test the renal urine concentration function, and carry out the differential diagnosis of renal function.

(4) For hemophilia and other bleeding diseases, this product can shorten the bleeding time and prevent bleeding. It can reduce the amount of intraoperative blood loss and postoperative oozing; especially in conjunction with reasonably controlled blood pressure during surgery, it can reduce intraoperative bleeding from different mechanisms, and reduce postoperative oozing, which can play a better role in blood protection.

Treatment of diabetes insipidus

Diabetes insipidus is primarily a disorder of water metabolism characterized by excess urine output, polydipsia, hypoosmolarity, and hypernatremia. Partial or complete deficiency of vasopressin (central diabetes insipidus), or renal insufficiency of vasopressin (nephrogenic diabetes insipidus) can be onset. Clinically, diabetes insipidus is similar to primary polydipsia, a condition in which excessive fluid intake is caused by a malfunction of the regulatory mechanism or abnormal thirst. Contrary to primary polydipsia, the increase in water intake in patients with diabetes insipidus is a corresponding response to changes in osmotic pressure or blood volume.


Product detail pictures:

OEM China Diphenylacetonitrile Uses - Desmopressin Acetate to Treat central Diabetes Insipidus – Gentolex detail pictures

OEM China Diphenylacetonitrile Uses - Desmopressin Acetate to Treat central Diabetes Insipidus – Gentolex detail pictures


Related Product Guide:

We keep on with our enterprise spirit of "Quality, Efficiency, Innovation and Integrity". We intention to create extra worth for our buyers with our prosperous resources, superior machinery, experienced workers and superb services for OEM China Diphenylacetonitrile Uses - Desmopressin Acetate to Treat central Diabetes Insipidus – Gentolex , The product will supply to all over the world, such as: Norway, Hongkong, Israel, In the future, we promise to keep offer the high quality and more cost-effective products, the more efficient after sales service to our all customers all over the world for the common development and the higher benefit.
  • In China, we have many partners, this company is the most satisfying to us, reliable quality and good credit, it is worth appreciation.
    5 Stars By Gill from Netherlands - 2017.12.19 11:10
    This supplier's raw material quality is stable and reliable, has always been in accordance with the requirements of our company to provide the goods that quality meet our requirements.
    5 Stars By Antonia from Jeddah - 2018.10.31 10:02
    Write your message here and send it to us